NovoCure
NVCR
267 hedge funds and large institutions have $3.78B invested in NovoCure in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 80 increasing their positions, 97 reducing their positions, and 58 closing their positions.
136% more call options, than puts
Call options by funds: $103M | Put options by funds: $43.8M
0.69% more ownership
Funds ownership: 84.88% → 85.57% (+0.69%)
10% less funds holding
Funds holding: 296 → 267 (-29)
18% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 97
30% less capital invested
Capital invested by funds: $5.38B → $3.78B (-$1.6B)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$72M |
| 2 |
Coatue Management
New York
|
+$55M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$33.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$32.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$31.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$164M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$14.2M |
| 4 |
BlackRock
New York
|
-$12.7M |
| 5 |
JP Morgan Chase
New York
|
-$11.9M |
NVCR Hedge Fund Activity: Q2 2023 in Review
267 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2023, worth a combined $3.78B — down 30% from $5.38B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of NVCR and 30 opened new positions — a net loss of 28 holders — while 97 trimmed existing stakes and 80 added.
The largest buyer was Capital International Investors, adding an estimated $72M. The largest seller was Capital World Investors, cutting an estimated $164M.
- 267 institutional investors held NovoCure (NVCR) as of Q2 2023, down from 296 in Q1 2023.
- Funds reported $3.78B of NovoCure stock for Q2 2023, down 30% quarter-over-quarter.
- 30 funds opened new NovoCure positions in Q2 2023 and 58 closed out, a net change of -28 holders.
- The largest NovoCure buyer in Q2 2023 was Capital International Investors, an estimated $72M added.
- The largest NovoCure seller in Q2 2023 was Capital World Investors, an estimated $164M sold.
Based on aggregated 13F filings for Q2 2023.